Bilateral simultaneous femoral diaphyseal fractures in a patient with long-term ibandronate use

Orthopedics

Volumn 33, Issue 10, 2010, Pages

  Patel, Vishal C ^a   Lazzarini, Adam M ^a  

^a WESTCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

AGED; ARTICLE; BONE TURNOVER; CASE REPORT; DRUG WITHDRAWAL; FEMALE; FEMUR FRACTURE; FRACTURE; HIP RADIOGRAPHY; HUMAN; LONG TERM CARE; OSTEOPOROSIS; PATHOPHYSIOLOGY; POSTMENOPAUSE OSTEOPOROSIS; SHORT COURSE THERAPY; BONE DEVELOPMENT; BONE NAIL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FRACTURE HEALING; INSTRUMENTATION; METHODOLOGY; MULTIPLE TRAUMA; OSTEOSYNTHESIS; RADIOGRAPHY;

AGED; BONE DENSITY CONSERVATION AGENTS; BONE DEVELOPMENT; BONE NAILS; DIPHOSPHONATES; FEMALE; FEMORAL FRACTURES; FRACTURE FIXATION, INTERNAL; FRACTURE HEALING; HUMANS; MULTIPLE TRAUMA;

EID: 77957990077     PISSN: 01477447     EISSN: None     Source Type: Journal    
DOI: 10.3928/01477447-20100826-31     Document Type: Article

References (19)

1. Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007; 65(3):369-376.
2. Russell RG, Mühlbauer RC, Bisaz S, Williams DA, Fleisch H. The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats. Calcif Tissue Res. 1970; 6(3):183-196.
3. Cheung RK, Leung KK, Lee KC, Chow TC. Sequential non-traumatic femoral shaft fractures in a patient on long-term alendronate. Hong Kong Med J. 2007; 13(6):485-489.
4. Goh SK, Yang KY, Koh JS, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br. 2007; 89(3):349-353. (Pubitemid 46563912)
5. Kwek EB, Goh SK, Koh JS, Png MA, Howe TS. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy [published online ahead of print January 28, 2008]? Injury. 2008; 39(2):224-231.
6. Ali T, Jay RH. Spontaneous femoral shaft fracture after long-term alendronate [published online ahead of print June 25, 2009]. Age Ageing. 2009; 38(5):625-626.
7. Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med. 2008; 358(12):1304-1306.
8. Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma. 2008; 22(5):346-350. (Pubitemid 351630250)
9. Sayed-Noor AS, Sjödén GO. Subtrochanteric displaced insufficiency fracture after long-term alendronate therapy - a case report. Acta Orthop. 2008; 79(4):565-567.
10. Schneider JP. Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate. Geriatrics. 2006; 61(1):31-33.
11. Goddard MS, Reid KR, Johnston JC, Khanuja HS. Atraumatic bilateral femur fracture in long-term bisphosphonate use. Orthopedics. 2009; 32(8). pii: orthosupersite.com/view.asp?rID=41933.
12. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy [published online ahead of print December 14, 2004]. J Clin Endocrinol Metab. 2005; 90(3):1294-1301.
13. Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone. 2001; 28(5):524-531.
14. Wasserman N, Yerramshetty J, Akkus O. Microcracks colocalize within highly mineralized regions of cortical bone tissue. Eur J Morphol. 2005; 42(1-2):43-51. (Pubitemid 41074377)
15. Ott SM. Long-term safety of bisphosphonates. J Clin Endocrinol Metab. 2005; 90(3):1897-1899.
16. Visekruna M, Wilson D, McKiernan FE. Severely suppressed bone turnover and atypical skeletal fragility [published online ahead of print June 3, 2008]. J Clin Endocrinol Metab. 2008; 93(8):2948-2952.
17. Ensrud KE, Barrett-Connor EL, Schwartz A, et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension [published online ahead of print March 29, 2004]. J Bone Miner Res. 2004; 19(8):1259-1269.
18. Capeci CM, Tejwani NC. Bilaterial low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J Bone Joint Surg Am. 2009; 91(11):2556-2561.
19. McClung MR, Bolognese MA, Sedarati F, Recker RR, Miller PD. Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss [published online ahead of print October 7, 2008]. Bone. 2009; 44(3):418-422.